Oncolife Highlights Rarecells in Salute Europa Interview with Founder Dr. Patrizia Paterlini, MD, PhD
Rarecells Announces New Clinical Data Showing Superior Sensitivity and Tumor Heterogeneity Detection by Synergistic Combination of ctDNA and ISET® CTC-DNA in Patients with Early-Stage Lung Cancer
Vanity Fair Italy Interviews Rarecells Founder Dr. Patrizia Paterlini
Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board
Press Release: Rarecells, Inc. Appoints Dr. Neil Kurtz to Board of Directors
Press Release: Rarecells announces Appointment of New Director to the Board
Press release : Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests
Press release : Rarecells, Inc. to fund a clinical study at Columbia University of its ISET® -AML test for early detection of Acute Myeloid Leukemia (AML)
Prof. Patrizia Paterlini-Brechot - Rarecells, Inc. - embarks on the search for the First Cell to beat cancer
Press release : ISET® technology makes Circulating Tumor Cells accessible to target PDAC mutant genes detection in pancreatic cancer with an accuracy demonstrated by a targeted scNGS
